Barclays PLC Cytek Biosciences, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 215,424 shares of CTKB stock, worth $926,323. This represents 0.0% of its overall portfolio holdings.

Number of Shares

215,424

Previous 201,359 6.99%

Holding current value

$926,323

Previous $1.12 Million 25.18%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$4.7 - $7.4 $66,105 - $104,081	14,065 Added 6.99%	215,424 $1.4 Million
Q3 2024 Nov 15, 2024	BUY	$4.73 - $6.73 $732,747 - $1.04 Million	154,915 Added 333.55%	201,359 $1.12 Million
Q2 2024 Aug 14, 2024	SELL	$5.3 - $6.91 $318,922 - $415,802	-60,174 Reduced 56.44%	46,444 $259,000
Q1 2024 May 15, 2024	SELL	$6.29 - $9.15 $520,340 - $756,933	-82,725 Reduced 43.69%	106,618 $715,000
Q4 2023 Feb 15, 2024	BUY	$4.1 - $9.51 $574,672 - $1.33 Million	140,164 Added 285.01%	189,343 $1.73 Million
Q3 2023 Nov 07, 2023	BUY	$5.52 - $9.5 $2,268 - $3,904	411 Added 0.84%	49,179 $271,000
Q2 2023 Aug 03, 2023	SELL	$6.69 - $11.99 $60,350 - $108,161	-9,021 Reduced 15.61%	48,768 $416,000
Q1 2023 May 04, 2023	BUY	$8.44 - $13.47 $228,977 - $365,441	27,130 Added 88.49%	57,789 $531,000
Q4 2022 Feb 13, 2023	BUY	$9.71 - $15.86 $250,692 - $409,473	25,818 Added 533.32%	30,659 $313,000
Q3 2022 Nov 03, 2022	SELL	$10.96 - $15.45 $140,397 - $197,914	-12,810 Reduced 72.57%	4,841 $71,000
Q2 2022 Aug 12, 2022	SELL	$7.41 - $11.56 $111,187 - $173,457	-15,005 Reduced 45.95%	17,651 $189,000
Q1 2022 May 16, 2022	BUY	$9.89 - $17.25 $322,967 - $563,316	32,656 New	32,656 $351,000

Others Institutions Holding CTKB

# of Institutions

151

Shares Held

74M

Call Options Held

Put Options Held

View Full List

About Cytek Biosciences, Inc.

Ticker CTKB
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 134,627,008
Market Cap $579M
Description
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...

More about CTKB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account